HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE)

Satellos Bioscience (NASDAQ:MSLE)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 87.30% from the company’s previous close.

MSLE has been the subject of several other research reports. Guggenheim began coverage on shares of Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price objective for the company. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Wells Fargo & Company set a $18.00 price target on shares of Satellos Bioscience in a report on Thursday, July 9th. Finally, Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Satellos Bioscience has an average rating of “Moderate Buy” and an average price target of $19.75.

Satellos Bioscience Price Performance

Shares of MSLE opened at $9.61 on Monday. The stock has a market cap of $200.27 million, a PE ratio of -5.00 and a beta of 1.51. Satellos Bioscience has a 1 year low of $4.84 and a 1 year high of $13.39. The business’s 50 day moving average price is $8.21.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). As a group, analysts expect that Satellos Bioscience will post -1.69 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,000 shares of the company’s stock after buying an additional 90,000 shares during the quarter. AWM Investment Company Inc. owned approximately 1.46% of Satellos Bioscience worth $2,338,000 as of its most recent SEC filing.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.